Literature DB >> 30661902

lncRNAPVT1 targets miR-152 to enhance chemoresistance of osteosarcoma to gemcitabine through activating c-MET/PI3K/AKT pathway.

Ze-Yu Sun1, Yue-Kui Jian2, Huan-Ye Zhu1, Bo Li3.   

Abstract

BACKGROUND: LncRNA PVT1 has been reported to be involved in a variety of biological processes, including cell proliferation, cell differentiation and cancer progression. However, the mechanism by which LncRNA PVT1 contributes to chemoresistance of osteosarcoma cell, has not been fully elucidated.
METHODS: We first generatedLncRNA PVT1-overexpressed MG63 cells and LncRNA PVT1 knockdown MG63/DOX cells. Then, we examined the effect of LncRNA PVT1 on cell viability and colony formation ability by MTT assay and soft agar assay, respectively. In addition, we performed flow cytometry analysis to detect apoptosis induced by GEM. Dual luciferase reporter assay and RIP were used to confirmed the interaction between LncRNA PVT1 and miR-152. Finally, we determined protein level of c-MET, p-PI3K, and p-AKT by westernblot.
RESULTS: LncRNA PVT1 overexpression promoted cell proliferation and exhibited the anti-apoptotic property in LncRNA PVT1-overexpressing MG63 cells treated with gemcitabine. While, LncRNA PVT1-depleted MG63/DOX cells treated with gemcitabine exhibited significant lower survival rate and high percentage of apoptosis. Next, we found that LncRNA PVT1 could target and downregulated the level of miR-152. Interestingly, miR-152 greatly rescued the biological outcomes of LncRNA PVT1 not only in MG63 but also in MG63/DOX cells. We observed that LncRNA PVT1 markedly induced PI3K/AKT pathway activation, which was abolished by miR-152 mimics overexpression. Finally, c-MET inhibitor was used to confirm the essential role of c-MET in LncRNA PVT1 and miR-152-regulated PI3K/AKT signaling.
CONCLUSION: We showed thatlncRNA PVT1 played a contributory role in chemoresistance of osteosarcoma cells through c-MET/PI3K/AKT pathway activation, which was largely dependent on miR-152. Our findings advance our understanding of how lncRNA PVT1 promotes chemoresistance of osteosarcoma cells and facilitate development of novel strategies for treating osteosarcoma.
Copyright © 2019. Published by Elsevier GmbH.

Entities:  

Keywords:  Chemoresistance; Osteosarcoma; PI3K/AKT pathway; lncRNA PVT1; miR-152

Mesh:

Substances:

Year:  2018        PMID: 30661902     DOI: 10.1016/j.prp.2018.12.013

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  21 in total

Review 1.  PVT1 Signaling Is a Mediator of Cancer Progression.

Authors:  Camille Derderian; Akintunde T Orunmuyi; E Oluwabunmi Olapade-Olaopa; Olorunseun O Ogunwobi
Journal:  Front Oncol       Date:  2019-06-12       Impact factor: 6.244

Review 2.  Role of non-coding RNAs and RNA modifiers in cancer therapy resistance.

Authors:  Xinyi Zhang; Kai Xie; Honghua Zhou; Yuwei Wu; Chan Li; Yating Liu; Zhaoya Liu; Qian Xu; Shuang Liu; Desheng Xiao; Yongguang Tao
Journal:  Mol Cancer       Date:  2020-03-02       Impact factor: 27.401

3.  LncRNA PVT1 Enhances Proliferation and Cisplatin Resistance via Regulating miR-194-5p/HIF1a Axis in Oral Squamous Cell Carcinoma.

Authors:  Fang Wang; Xin Ji; Jingjing Wang; Xiangrui Ma; Yong Yang; Jinhua Zuo; Jun Cui
Journal:  Onco Targets Ther       Date:  2020-01-09       Impact factor: 4.147

4.  The expression of miRNA-152-3p and miRNA-185 in tumor tissues versus margin tissues of patients with chemo-treated breast cancer.

Authors:  Asma Safi; Soheila Delgir; Khandan Ilkhani; Azam Samei; Seyyed Reza Mousavi; Zahra Zeynali-Khasraghi; Milad Bastami; Mohammad Reza Alivand
Journal:  BMC Res Notes       Date:  2021-06-16

Review 5.  Long noncoding RNAs in osteosarcoma via various signaling pathways.

Authors:  Jinming Han; Xiaohan Shen
Journal:  J Clin Lab Anal       Date:  2020-04-06       Impact factor: 2.352

Review 6.  Chemoresistance Mediated by ceRNA Networks Associated With the PVT1 Locus.

Authors:  Olorunseun O Ogunwobi; Adithya Kumar
Journal:  Front Oncol       Date:  2019-08-27       Impact factor: 6.244

7.  LncRNA AGAP2-AS1 augments cell viability and mobility, and confers gemcitabine resistance by inhibiting miR-497 in colorectal cancer.

Authors:  Sen Hong; Zhenkun Yan; YuMei Song; MiaoMiao Bi; Shiquan Li
Journal:  Aging (Albany NY)       Date:  2020-03-23       Impact factor: 5.682

8.  Curcumol inhibits the proliferation and metastasis of melanoma via the miR-152-3p/PI3K/AKT and ERK/NF-κB signaling pathways.

Authors:  Ning Ning; Sulai Liu; Xiehong Liu; Zeyu Tian; Yu Jiang; Nanhui Yu; Boyu Tan; Hao Feng; Xing Feng; Lianhong Zou
Journal:  J Cancer       Date:  2020-01-14       Impact factor: 4.207

Review 9.  Crosstalk Mechanisms Between HGF/c-Met Axis and ncRNAs in Malignancy.

Authors:  Xin Liu; Ranran Sun; Jianan Chen; Liwen Liu; Xichun Cui; Shen Shen; Guangying Cui; Zhigang Ren; Zujiang Yu
Journal:  Front Cell Dev Biol       Date:  2020-01-31

Review 10.  Long Non-coding RNA PVT1 as a Prognostic and Therapeutic Target in Pediatric Cancer.

Authors:  Ariadna Boloix; Marc Masanas; Carlos Jiménez; Roberta Antonelli; Aroa Soriano; Josep Roma; Josep Sánchez de Toledo; Soledad Gallego; Miguel F Segura
Journal:  Front Oncol       Date:  2019-11-06       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.